Company profile: Esperion Therapeutics
1.1 - Company Overview
Company description
- Provider of pharmaceutical products for cardiovascular and metabolic diseases, including bempedoic acid to lower LDL-cholesterol in hypercholesterolemia patients inadequately treated with current lipid-modifying therapies, and a fixed-dose combination of bempedoic acid and ezetimibe to further reduce LDL-cholesterol.
Products and services
- Bempedoic Acid and Ezetimibe Combination: A fixed-dose combination therapy that combines bempedoic acid with ezetimibe to further reduce LDL-cholesterol levels in patients
- Bempedoic Acid: A pharmaceutical medication engineered to lower LDL-cholesterol levels in patients with hypercholesterolemia who are inadequately treated with current lipid-modifying therapies
- Pharmaceutical Discovery and Development: Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases, a pharmaceutical-focused capability
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Esperion Therapeutics
Laminar
HQ: United States
Website
- Description: Provider of devices that eliminate the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Laminar company profile →
Instylla
HQ: United States
Website
- Description: Provider of next-generation liquid embolics for interventional radiology. Offers the Embrace Hydrogel Embolic System (HES), a device that embolizes hypervascular tumors and peripheral arterial bleeds by forming a soft hydrogel to fill vessel lumens during embolization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instylla company profile →
Access Vascular
HQ: United States
Website
- Description: Provider of medical devices utilizing novel bulk hydrophilic-based technology to improve venous access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Access Vascular company profile →
Verathon
HQ: United States
Website
- Description: Provider of medical devices and services, designing, manufacturing and distributing solutions for airway management and bladder volume measurement, including GlideScope video laryngoscopes, GlideScope Core airway visualization systems, GlideScope Go 2 for EMS, GlideScope Spectrum QC single-use laryngoscopes, BFlex single-use bronchoscopes, and BladderScan ultrasound devices with AI.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verathon company profile →
Sanifit
HQ: Spain
Website
- Description: Provider of biotechnology therapies for calcification disorders, developing SNF472 in phase 3 for calciphylaxis associated with chronic kidney disease and dialysis, and for peripheral artery disease in end-stage kidney disease, aiming to reduce arterial and cardiovascular calcification; supported by the CaLIPSO phase 2b trial showing significant reduction in coronary artery calcium progression in dialysis patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sanifit company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Esperion Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Esperion Therapeutics
2.2 - Growth funds investing in similar companies to Esperion Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Esperion Therapeutics
4.2 - Public trading comparable groups for Esperion Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →